H3C6

Across TCGA pan-cancer cohorts, H3C6 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated H3C6 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher H3C6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated H3C6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

UCS, ACC, and LUAD are the cancer types where H3C6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
LUAD	OS	Median	All	0.249	0.699	.017	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
THCA	OS	Median	All	0.342	0.955	<.001	3	view →
HNSC	DFS	Median	II,III,IV	1.000	0.585	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

H3C6–UCS (DFS)

Open the UCS breakdown →